Application of 68Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke

Theranostics

Volumn 4, Issue 8, 2014, Pages 778-786

  Sun, Yi ^a   Zeng, Yong ^a   Zhu, Yicheng ^a   Feng, Feng ^a   Xu, Weihai ^a   Wu, Chenxi ^a   Xing, Bing ^a   Zhang, Weihong ^a   Wu, Peiling ^a   Cui, Liying ^a   Wang, Renzhi ^a   Li, Fang ^a   Chen, Xiaoyuan ^b   Zhu, Zhaohui ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Angiogenesis; Myocardial infarction; PET CT; Stroke

Indexed keywords

GALLIUM 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID POLYETHYLENE GLYCOL 3 [CYCLIC(ARGINYLGLYCYLASPARTYL DEXTRO TYROSYLLYSINE)] 2 GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 68GA-1,4,7-TRIAZACYCLONONANE-1,4-7-TRIACETIC ACID-ISOTHIOCYANATOBENZYL-C(ARG-GLY-ASP-TYR-LYS); COORDINATION COMPOUND; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIAC IMAGING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMAGE ANALYSIS; MALE; MOLECULAR IMAGING; NEUROIMAGING; PATIENT ASSESSMENT; PEAK STANDARDIZED UPTAKE VALUE; RADIOLOGICAL PARAMETERS; REPEAT PROCEDURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COORDINATION COMPLEXES; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; STROKE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902530494     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8809     Document Type: Article

References (38)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-2128.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years(DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2197-2223.
3. Jung C, Kwon BJ, Han MH. Evidence-based changes in devices and methods of endovascular recanalization therapy. Neurointervention. 2012; 7: 68-76.
4. Silvestre JS, Smadja DM, Lévy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013; 93: 1743-1802.
5. Backer MV, Backer JM. Imaging key biomarkers of tumor angiogenesis. Theranostics. 2012; 2: 502-515.
6. Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013; 201: W183-191.
7. Gao H, Lang L, Guo N, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012; 39: 683-692.
8. Cai W, Guzman R, Hsu AR, et al. Positron emission tomography imaging of poststroke angiogenesis. Stroke. 2009; 40: 270-277.
9. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47.
10. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res. 2006; 312: 651-658.
11. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin alphaVbeta3 expression. Theranostics. 2011; 1: 48-57.
12. Zhou Y, Chakraborty S, Liu S. Radiolabeled Cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics, 2011;1: 58-82.
13. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. BioconjugChem. 2009;20:2199-2213.
14. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008; 51: 7980-7990.
15. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetricstudies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3)integrin levels. Radiology. 2011; 260: 182-191.
16. Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin alphaVbeta3 expression and glucosemetabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008; 49: 22-29.
17. Lang L, Li W, Guo N, et al. Comparison study of [18F] FAl-NOTA-PRGD2, [18F] FPPRGD2, and [68Ga] Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjugate chemistry. 2011; 22(12): 2415-2422.
18. Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis. 2014; doi: 10.1136/annrheumdis-2013-204820. [Epub ahead of print]
19. Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004; 6: 350-359.
20. Lang L, Li W, Jia HM, et al. New Methods for Labeling RGD Peptides with Bromine-76. Theranostics, 2011. 1: 341-53.
21. Jacobson O, Zhu L, Niu G, et al. MicroPET imaging of integrin alpha(v)beta(3) expressing tumors using (89)Zr-RGD peptides. Mol Imaging Biol. 2010;13:1224-1233.
22. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ; Study Group. Anopen-label, ulticenter, phase 2a study to assess the feasibility of imagingmetastases in late-stage cancer patients with the alpha v beta 3-selectiveangiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40-46.
23. JiaB, LiuZ, ZhuZ, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol. 2011; 13: 730-736.
24. Terry SY, Abiraj K, Frielink C, et al. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014; 55: 281-286.
25. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008; 49: 879-886.
26. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients withsquamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
27. Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012; 53: 787-795.
28. Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013; 54: 691-698.
29. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lungcancer: a multicenter study. J Nucl Med. 2012;53:716-722.
30. Hou Y, Zhu Z, Jin X, Wang R, Xing B. Combined 18F-FDG PET/CT and 99mTc 3PRGD2 SPECT/CT imaging in a case of pituitary metastases. Clin Nucl Med. 2013;38:550-552.
31. Jin X, Meng Y, Zhu Z, Jing H, Li F. Elevated 99mTc 3PRGD2 activity in benignmetastasizing leiomyoma. Clin Nucl Med. 2013;38:117-119.
32. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting αvβ3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J.2008; 29: 2201.
33. Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol. 2010; 17: 1065-72.
34. Beer AJ, Pelisek J, Heider P, et al. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging. 2014; [Epub ahead of print]
35. Choi H, Phi JH, Paeng JC, et al. Imaging of integrin expression using positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013; 12: 213-217.
36. Liu Z, Jia B, Shi J, et al. Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010; 21: 548-555.
37. van den Borne SW, Isobe S, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008; 52: 2017-2028.
38. van den Borne SW, Isobe S, Zandbergen HR, et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging. 2009; 2: 187-198.